Immunomedics Revenue and Competitors
Estimated Revenue & Valuation
- Immunomedics's estimated annual revenue is currently $34.6M per year.
- Immunomedics received $125.0M in venture funding in May 2017.
- Immunomedics's estimated revenue per employee is $288,042
- Immunomedics's total funding is $30M.
Employee Data
- Immunomedics has 120 Employees.
- Immunomedics grew their employee count by -8% last year.
Immunomedics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $10.9M | 70 | 0% | N/A | N/A |
#2 | $0.9M | 6 | -14% | N/A | N/A |
#3 | $11.9M | 77 | -6% | N/A | N/A |
#4 | $106.8M | 492 | 23% | N/A | N/A |
#5 | $1.4M | 9 | 29% | N/A | N/A |
#6 | $0.9M | 6 | 200% | N/A | N/A |
#7 | $14.7M | 68 | -23% | $206.4M | N/A |
#8 | $492.2M | 1461 | 18% | $568M | N/A |
#9 | $2.5M | 16 | 0% | N/A | N/A |
#10 | $4.5M | 29 | 7% | N/A | N/A |
What Is Immunomedics?
Immunomedics is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer and other serious diseases. Immunomedics corporate objective is to become a fully-integrated biopharmaceutical company and a leader in the field of antibody-drug conjugates.
keywords:Biotechnology,Cleantech,Healthcare,Medical Diagnostics,Pharmaceuticals,Wind Power$30M
Total Funding
120
Number of Employees
$34.6M
Revenue (est)
-8%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Immunomedics News
Gilead raised eyebrows in 2020 when it agreed to buy Immunomedics for about $21 billion, a substantial premium for a company that was...
Under a proposed settlement, Gilead Sciences' Immunomedics would shell out $4 million to resolve a lawsuit alleging it violated securities laws...
Immunomedics Inc. investors who say the company misled them about cancer drug data presentations asked a federal judge in New Jersey for...
Immunomedics, Inc. IMMU was a big mover last session, as the company saw its shares rise more than 6% on the day. The move came on solid ...
12, 2019 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $27.2M | 120 | 58% | N/A |
#2 | $12.2M | 122 | 9% | N/A |
#3 | $62M | 342 | 2% | N/A |
#4 | $114.5M | 436 | -4% | N/A |
#5 | $135.4M | 539 | 10% | N/A |
Immunomedics Funding
Date | Amount | Round | Lead Investors | Reference |
---|---|---|---|---|
2004-01-15 | $10.0M | notes | Article | |
2005-04-28 | $36.7M | Undisclosed | Multiple | Article |
2014-05-05 | $30.2M | Undisclosed | Article | |
2015-02-09 | $96.4M | Undisclosed | Goldman, Sachs & Co. | Article |
2017-05-08 | $125.0M | Undisclosed | Article |